VIVOLTA develops and manufactures electrospun medical products and operates as a contract development and manufacturing organization (CDMO) for clients. It uses a proprietary, fully automated MediSpin™ production platform—described in the article as the world’s first—to enable high-throughput manufacturing of tubular electrospun products such as vascular stent grafts and prosthetic heart valves. In 2021 the company transitioned from an equipment manufacturer (formerly IME) into a CDMO and has secured development partnerships with leading medical device manufacturers and startups. VIVOLTA is concentrating on near-term application areas including cardiovascular medicine, soft tissue repair and reconstruction, orthopaedic sports medicine, and advanced drug delivery systems. The new funding is intended to strengthen application development, engineering, commercial support, quality, regulatory, and manufacturing capabilities and to expand ISO class 7 production area footprint in preparation for clinical and commercial launches over the coming three years. Shareholders named in the article include TIIN Capital, Lumana Invest, Borski Fund, and Brabantse Ontwikkelings Maatschappij. IME Medical Electrospinning develops electrospun, fiber-based medical device solutions that mimic the human extracellular matrix in nanometer and micrometer format for implants and membranes. The company applies specific polymers to produce scaffolds used in heart valves, blood vessels, nerves, tendons, skin and bone repair. Its MediSpin™ XL platform was developed for MedTech industrial manufacturing and ensures firm control of critical electrospinning parameters, producing identical and consistent end-products. The MediSpin XL platform is now also suitable for pharmaceutical drug-delivery applications. Customers and scientific partners include the MedTech and Pharma industry, scientists and health institutions. The business is led by Managing Directors Ramon Solberg and Judith Heikoop.

Total raised

$11M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2023